| 6.05 -0.1 (-1.63%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.52  |
1-year : | 8.78 |
| Resists | First : | 6.44 |
Second : | 7.52 |
| Pivot price | 5.01 |
|||
| Supports | First : | 4.87 |
Second : | 3.91 |
| MAs | MA(5) : | 5.67 |
MA(20) : | 4.85 |
| MA(100) : | 3.68 |
MA(250) : | 3.38 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 92.4 |
D(3) : | 96.2 |
| RSI | RSI(14): 82.1 |
|||
| 52-week | High : | 6.44 | Low : | 2.45 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVIR ] has closed below upper band by 2.0%. Bollinger Bands are 253.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.45 - 6.48 | 6.48 - 6.5 |
| Low: | 5.94 - 5.98 | 5.98 - 6 |
| Close: | 5.99 - 6.05 | 6.05 - 6.09 |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Tue, 10 Mar 2026
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why - MarketBeat
Mon, 09 Mar 2026
Atea Pharmaceuticals (AVIR) Price Target Raised by Evercore ISI - GuruFocus
Sat, 07 Mar 2026
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript - insidermonkey.com
Thu, 05 Mar 2026
AVIR: Phase 3 HCV trials near completion, with robust cash and new HEV candidate advancing - TradingView
Thu, 05 Mar 2026
Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss - TradingView
Thu, 05 Mar 2026
Atea Pharmaceuticals (Nasdaq: AVIR) narrows 2025 loss and advances HCV, HEV pipeline - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 13.4 (%) |
| Held by Institutions | 78.2 (%) |
| Shares Short | 7,720 (K) |
| Shares Short P.Month | 7,300 (K) |
| EPS | -1.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.52 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.8 % |
| Return on Equity (ttm) | -44.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.88 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -132 (M) |
| Levered Free Cash Flow | -71 (M) |
| PE Ratio | -3.42 |
| PEG Ratio | 0 |
| Price to Book value | 1.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|